Retraction: Does compensatory hyperparathyroidism predispose to ischemic stroke? (International Journal of Gynecology & Obstetrics, (2008), 103, (213-216), 10.1016/j.ijgo.2008.07.011);Isosorbide mononitrate versus alendronate for postmenopausal osteoporosis

International Journal of Gynecology and Obstetrics

Volumn 103, Issue 3, 2008, Pages 213-216

  Nabhan, Ashraf F ^a   Rabie, Noha H ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Alendronate; Bone mineral density; Isosorbide mononitrate; Nitric oxide donors; Postmenopausal osteoporosis

Indexed keywords

ALENDRONIC ACID; ISOSORBIDE 5 NITRATE; PARACETAMOL;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 55949102260     PISSN: 00207292     EISSN: 18793479     Source Type: Journal    
DOI: 10.1002/ijgo.15297     Document Type: Erratum

References (25)

1. Greenblatt D. Treatment of postmenopausal osteoporosis. Pharmacotherapy 25 4 (2005) 574-584
2. Delaney M.F. Strategies for the prevention and treatment of osteoporosis during early postmenopause. Am J Obstet Gynecol 194 2 Suppl (2006) S12-S23
3. Compston J. How to manage osteoporosis after the menopause. Best Pract Res Clin Rheumatol 19 6 (2005) 1007-1019
4. Kamel H.K. Update on osteoporosis management in long-term care: focus on bisphosphonates. J Am Med Dir Assoc 8 7 (2007) 434-440
5. Reid I.R. Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety. Expert Opin Drug Saf 1 1 (2002) 93-107
6. Vestergaard P. Anti-resorptive therapy for the prevention of postmenopausal osteoporosis: when should treatment begin?. Treat Endocrinol 4 5 (2005) 263-277
7. Cranney A., Wells G., Willan A., Griffith L., Zytaruk N., Robinson V., et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23 4 (2002) 508-516
8. Papapoulos S.E., Quandt S.A., Liberman U.A., Hochberg M.C., and Thompson D.E. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 16 5 (2005) 468-474
9. Wells G.A., Cranney A., Peterson J., Boucher M., Shea B., Robinson V., et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 1 (2008) CD001155
10. Aguirre J., Buttery L., O'Shaughnessy M., Afzal F., Fernandez de Marticorena I., Hukkanen M., et al. Endothelial nitric oxide synthase gene-deficient mice demonstrate marked retardation in postnatal bone formation, reduced bone volume, and defects in osteoblast maturation and activity. Am J Pathol 158 1 (2001) 247-257
11. Cho K., Demissie S., Dupuis J., Cupples L.A., Kathiresan S., Beck T.J., et al. Polymorphisms in the endothelial nitric oxide synthase gene and bone density/ultrasound and geometry in humans. Bone 42 1 (2008) 53-60
12. Taylor B.C., Schreiner P.J., Zmuda J.M., Li J., Moffett S.P., Beck T.J., et al. Association of endothelial nitric oxide synthase genotypes with bone mineral density, bone loss, hip structure, and risk of fracture in older women: the SOF study. Bone 39 1 (2006) 174-180
13. Armour K.E., Armour K.J., Gallagher M.E., Godecke A., Helfrich M.H., Reid D.M., et al. Defective bone formation and anabolic response to exogenous estrogen in mice with targeted disruption of endothelial nitric oxide synthase. Endocrinology 142 2 (2001) 760-766
14. van't Hof R.J., and Ralston S.H. Nitric oxide and bone. Immunology 103 3 (2001) 255-261
15. Simoncini T., and Genazzani A.R. Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase. J Clin Endocrinol Metab 85 8 (2000) 2966-2969
16. Nomura S., and Takano-Yamamoto T. Molecular events caused by mechanical stress in bone. Matrix Biol 19 2 (2000) 91-96
17. Fan X., Roy E., Zhu L., Murphy T.C., Ackert-Bicknell C., Hart C.M., et al. Nitric oxide regulates receptor activator of nuclear factor-kappaB ligand and osteoprotegerin expression in bone marrow stromal cells. Endocrinology 145 2 (2004) 751-759
18. Hao Y.J., Tang Y., Chen F.B., and Pei F.X. Different doses of nitric oxide donor prevent osteoporosis in ovariectomized rats. Clin Orthop Relat Res 435 (2005) 226-231
19. Hukkanen M., Platts L.A., Lawes T., Girgis S.I., Konttinen Y.T., Goodship A.E., et al. Effect of nitric oxide donor nitroglycerin on bone mineral density in a rat model of estrogen deficiency-induced osteopenia. Bone 32 2 (2003) 142-149
20. Wimalawansa S.J. Nitroglycerin therapy is as efficacious as standard estrogen replacement therapy (Premarin) in prevention of oophorectomy-induced bone loss: a human pilot clinical study. J Bone Miner Res 15 11 (2000) 2240-2244
21. Jamal S.A., Hamilton C.J., Black D., and Cummings S.R. The effects of organic nitrates on osteoporosis: a randomized controlled trial [ISRCTN94484747]. Trials 7 (2006) 10
22. Jamal S.A., Cummings S.R., and Hawker G.A. Isosorbide mononitrate increases bone formation and decreases bone resorption in postmenopausal women: a randomized trial. J Bone Miner Res 19 9 (2004) 1512-1517
23. World Health Organization. Prevention and management of osteoporosis. World Health Organ Tech Rep Ser 921 (2003) 1-164
24. Rejnmark L., Vestergaard P., and Mosekilde L. Decreased fracture risk in users of organic nitrates: a nationwide case-control study. J Bone Miner Res 21 11 (2006) 1811-1817
25. Csont T., and Ferdinandy P. Cardioprotective effects of glyceryl trinitrate: beyond vascular nitrate tolerance. Pharmacol Ther 105 1 (2005) 57-68